---
title: "Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Dosing and administration questions"
description: "Dosing and administration questions on Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Switching, and Treatment combinations. Questions: What is the FDA-approved Gardasil 9 dosing schedule by age? How many Gardasil 9 doses are given from age 15 through 45? On the 2-dose Gardasil 9 schedule, what if dose 2 is given early? What do data show for Gardasil 9 after a prior Gardasil series? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Dosing and administration questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Gardasil 9](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf)

Dosing and administration questions that apply to every indication of Gardasil 9 are on [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), all indications: Dosing and administration](https://www.evicenter.com/medical-information/gardasil-9/dosing-and-administration).

## Dosing

<a id="gardasil9-dosing-schedule"></a>

### What is the FDA-approved Gardasil 9 dosing schedule by age?

> “Patients 9 through 14 years
>
> Regimen	Schedule
> 2-dose	0, 6 to 12 months<sup>a</sup>
> 3-dose	0, 2, 6 months
>
> <sup>a</sup>If the second dose is administered earlier than 5 months after the first dose, administer a third dose at least 4 months after the second dose.
>
> Patients 15 through 45 years
>
> Regimen	Schedule
> 3-dose	0, 2, 6 months”

Source: [GARDASIL 9: Dosage and Administration for GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), captured 2026-11-13](https://www.merckvaccines.com/gardasil9/dosage-administration/#:~:text=Patients%209%20through%2014%20years,0%2C%202%2C%206%20months)

Note: The same manufacturer page states that CDC recommended dosing for Gardasil 9 differs from the FDA-approved dosing shown here.

<a id="gardasil9-adult-doses"></a>

### How many Gardasil 9 doses are given from age 15 through 45?

> “For individuals 15 through 45 years of age, GARDASIL 9 is administered using a 3-dose schedule at 0, 2 months, and 6 months.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=For%20individuals%2015%20through%2045,2%20months%2C%20and%206%20months.)

Note: The Gardasil 9 dosage page states that CDC recommended dosing for Gardasil 9 differs from the FDA-approved dosing.

<a id="gardasil9-second-dose-early"></a>

### On the 2-dose Gardasil 9 schedule, what if dose 2 is given early?

> “For the 2-dose schedule, the second dose should be administered 6–12 months after the first dose. If the second dose is administered less than 5 months after the first dose, a third dose should be given at least 4 months after the second dose.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=For%20the%202%2Ddose%20schedule%2C%20the,months%20after%20the%20second%20dose.)

## Switching

<a id="gardasil9-after-gardasil-series"></a>

### What do data show for Gardasil 9 after a prior Gardasil series?

Applies to: Girls and women 12 through 26 years of age previously vaccinated with Gardasil (Study 4)

> “Safety and immunogenicity were assessed in individuals who completed a three-dose vaccination
> series with GARDASIL 9 and had previously completed a three-dose vaccination series with GARDASIL
> [see Adverse Reactions (6.1) and Clinical Studies (14.6)].”

Source: [GARDASIL 9: Prescribing information, page 3, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=3)

> “Study 4 evaluated the immunogenicity of 3 doses of GARDASIL 9 in 921 girls and women (12 through
> 26 years of age) who had previously been vaccinated with 3 doses of GARDASIL. Prior to enrollment in
> the study, over 99% of subjects had received three injections of GARDASIL within a one year period. The
> time interval between the last injection of GARDASIL and the first injection of GARDASIL 9 ranged from
> approximately 12 to 36 months.
> Seropositivity to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in the per protocol population ranged
> from 98.3 to 100% by Month 7 in individuals who received GARDASIL 9. The anti-HPV 31, 33, 45, 52 and
> 58 GMTs for the population previously vaccinated with GARDASIL were 25-63% of the GMTs in the
> combined populations from Studies 1, 2, 3, and 5, who had not previously received GARDASIL, although
> the clinical relevance of these differences is unknown. Efficacy of GARDASIL 9 in preventing infection
> and disease related to HPV Types 31, 33, 45, 52, and 58 in individuals previously vaccinated with
> GARDASIL has not been assessed.”

Source: [GARDASIL 9: Prescribing information, page 23, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=23)

> “Overall, the safety profile was
> similar between individuals vaccinated with GARDASIL 9 who were previously vaccinated with
> GARDASIL and those who were naïve to HPV vaccination with the exception of numerically higher rates
> of injection-site swelling and erythema among individuals who were previously vaccinated with
> GARDASIL (Tables 1 and 4).”

Source: [GARDASIL 9: Prescribing information, page 8, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=8)

## Treatment combinations

<a id="gardasil9-menactra-adacel"></a>

### Gardasil 9 with Menactra and Adacel: what did Study 5 show (ages 11-15)?

Applies to: Boys and girls 11 through 15 years of age given Gardasil 9 with Menactra and Adacel (Study 5)

> “Concomitant administration of GARDASIL 9, at a separate injection site, did not interfere with the antibody responses to any of these vaccines when compared with nonconcomitant administration of GARDASIL 9:
>
> Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine]
> Adacel [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap)]
>
> The rates of injection-site adverse reactions were similar between the concomitant group and nonconcomitant group (vaccination with GARDASIL 9 separated from vaccination with Menactra and Adacel by 1 month) with the exception of an increased rate of swelling reported at the injection site for GARDASIL 9 in the concomitant group (14.4%) compared to the nonconcomitant group (9.4%). The majority of injection-site swelling adverse reactions were reported as being mild to moderate in intensity.”

Source: [GARDASIL 9: Dosage and Administration for GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), captured 2026-11-13](https://www.merckvaccines.com/gardasil9/dosage-administration/#:~:text=Concomitant%20administration%20of%20GARDASIL%209%2C,mild%20to%20moderate%20in%20intensity.)

> “In Study 5, the safety and immunogenicity of co-administration of GARDASIL 9 with Menactra
> [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] and
> Adacel [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)]
> (same visit, injections at separate sites) were evaluated in 1,237 boys and girls 11 through 15 years of
> age at enrollment.”

Source: [GARDASIL 9: Prescribing information, page 25, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=25)

## Related pages
- [Medical information: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): Human papillomavirus vaccination](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination)
- [Indication](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/safety)
- [Specific populations](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/drug-interactions)
- [Guidelines](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/guidelines)
